Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome.

Published in: Diseases (Basel, Switzerland) (2023)

Fenofibrate in a real-world setting significantly reduced TG, LDL-C, and non-HDL-C levels. In addition, a C-reactive protein level reduction of 39% was achieved.

Keyphrases

metabolic syndrome
insulin resistance
clinical practice
adipose tissue
combination therapy
cardiovascular risk factors
skeletal muscle
replacement therapy